Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Cell cycle regulation is orchestrated by a complex network of interactions between proteins,
enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has
recently gained interest, and different DDR inhibitors have been developed. Among them …

A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …

Poly (ADP-ribose) polymerase inhibitors (PARPi) have significantly changed the treatment
landscape for tumours harbouring defects in genes involved in homologous repair (HR) …

Metastasis formation is the main cause of cancer-related death in patients with solid
tumours. At the beginning of this process, cancer cells escape from the primary tumour to the …

Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP
have modest single-agent activity. We performed a phase I/II trial of combination olaparib …